{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:03:06Z","timestamp":1788850986085,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Institut f\u00fcr Ern\u00e4hrungsforschung Potsdam-Rehbr\u00fccke (DIfE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread chronic liver disorder spanning simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Suitable animal models are crucial for therapeutic development, yet many fail to reproduce progression to fibrosing MASH. Here, we employed the STAM model in male C57BL\/6J mice to simulate MASLD and investigated whether a high-fat, high-cholesterol (HFHC) diet would intensify disease progression compared with a standard high-fat (HF) diet. HFHC feeding in the STAM model accelerated hepatic lipid accumulation, crown-like structure formation, inflammation, and fibrosis, as demonstrated by histological analyses. Transcriptomic profiling and pathway enrichment confirmed activation of lipid and cholesterol metabolism, regulation of TNF production, and inflammatory signaling. Reactome analysis further indicated alterations in extracellular matrix formation and immune system pathways, consistent with advanced fibrotic progression. In summary, integration of HFHC feeding with the STAM model produced a more severe liver phenotype that better mirrors the pathological spectrum of MASLD. This optimized model offers a valuable platform for preclinical testing of therapeutic candidates targeting MASH and fibrosis, with potential to accelerate drug development and to improve treatment strategies for MASLD.<\/jats:p>","DOI":"10.1038\/s41598-026-45979-z","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:45:21Z","timestamp":1775069121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cholesterol-rich diet exacerbates steatohepatitis in the STAM mouse model"],"prefix":"10.1038","volume":"16","author":[{"given":"Wenke","family":"Jonas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Gottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"J\u00e4hnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Sch\u00fcrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"45979_CR1","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba, R., Friedman, S. L. & Shulman, G. I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537\u20132564 (2021).","journal-title":"Cell"},{"key":"45979_CR2","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1210\/jc.2015-3444","volume":"101","author":"KA Loomis","year":"2016","unstructured":"Loomis, K. A. et al. Body mass index and risk of nonalcoholic fatty liver disease: Two electronic health record prospective studies. J. Clin. Endocrinol. Metab. 101, 945\u2013952 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"45979_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","volume":"14","author":"H Tilg","year":"2017","unstructured":"Tilg, H., Moschen, A. R. & Roden, M. NAFLD and diabetes mellitus. Nat. Rev. Gastroenterol. Hepatol. 14, 32\u201342 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"45979_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","volume":"41","author":"A Mantovani","year":"2018","unstructured":"Mantovani, A., Byrne, C. D., Bonora, E. & Targher, G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis. Diabetes Care. 41, 372\u2013382 (2018).","journal-title":"Diabetes Care"},{"key":"45979_CR5","doi-asserted-by":"publisher","unstructured":"Younossi, Z. M. Non-alcoholic fatty liver disease \u2013 A global public health perspective. J. Hepatol. 70, 531\u2013544 https:\/\/doi.org\/10.1016\/j.jhep.2018.10.033 (2019).","DOI":"10.1016\/j.jhep.2018.10.033"},{"key":"45979_CR6","doi-asserted-by":"crossref","unstructured":"Gancheva, S., Roden, M. & Castera, L. Diabetes as a risk factor for MASH progression. Diabetes Res. Clin. Pract. 217, (2024).","DOI":"10.1016\/j.diabres.2024.111846"},{"key":"45979_CR7","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1111\/liv.14600","volume":"40","author":"LS Chiu","year":"2020","unstructured":"Chiu, L. S. et al. The association of non-alcoholic fatty liver disease and cardiac structure and function\u2014Framingham heart study. Liver Int. 40, 2445\u20132454 (2020).","journal-title":"Liver Int."},{"key":"45979_CR8","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","volume":"17","author":"Y Lee","year":"2019","unstructured":"Lee, Y. et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 17, 1040\u20131060e11 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"45979_CR9","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","volume":"401","author":"O Verrastro","year":"2023","unstructured":"Verrastro, O. et al. Bariatric\u2013metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 401, 1786\u20131797 (2023).","journal-title":"Lancet"},{"key":"45979_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome, P. N. et al. A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl. J. Med. 384, 113\u20131124 (2021).","journal-title":"N Engl. J. Med."},{"key":"45979_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba, R. et al. Semaglutide 2\u00b74\u00a0mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 8, 511\u2013522 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"45979_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba, R. et al. Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis. N Engl. J. Med. 391, 299\u2013310 (2024).","journal-title":"N Engl. J. Med."},{"key":"45979_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w","author":"Y Xie","year":"2025","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03412-w (2025).","journal-title":"Nat. Med."},{"key":"45979_CR14","doi-asserted-by":"publisher","unstructured":"Soret, P. A., Magusto, J., Housset, C. & Gautheron, J. In vitro and in vivo models of non-alcoholic fatty liver disease: A critical appraisal. J. Clin. Med. 10, 1\u201318 https:\/\/doi.org\/10.3390\/jcm10010036 (2021).","DOI":"10.3390\/jcm10010036"},{"key":"45979_CR15","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41587-023-01680-4","volume":"41","author":"D Hendriks","year":"2023","unstructured":"Hendriks, D. et al. Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis. Nat. Biotechnol. 41, 1567\u20131581 (2023).","journal-title":"Nat. Biotechnol."},{"key":"45979_CR16","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/s42255-022-00700-y","volume":"4","author":"S Gallage","year":"2022","unstructured":"Gallage, S. et al. A researcher\u2019s guide to preclinical mouse NASH models. Nat. Metab. 4, 1632\u20131649 (2022).","journal-title":"Nat. Metab."},{"key":"45979_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00795-013-0016-1","volume":"46","author":"M Fujii","year":"2013","unstructured":"Fujii, M. et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med. Mol. Morphol. 46, 141\u2013152 (2013).","journal-title":"Med. Mol. Morphol."},{"key":"45979_CR18","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.jhep.2014.07.024","volume":"61","author":"LT Gan","year":"2014","unstructured":"Gan, L. T. et al. Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. J. Hepatol. 61, 1376\u20131384 (2014).","journal-title":"J. Hepatol."},{"key":"45979_CR19","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/hep.21763","volume":"46","author":"P Puri","year":"2007","unstructured":"Puri, P. et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46, 1081\u20131090 (2007).","journal-title":"Hepatology"},{"key":"45979_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/hep.22363","volume":"48","author":"K Wouters","year":"2008","unstructured":"Wouters, K. et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48, 474\u2013486 (2008).","journal-title":"Hepatology"},{"key":"45979_CR21","doi-asserted-by":"crossref","unstructured":"Henkel, J. et al. Soybean oil-derived poly-unsaturated fatty acids enhance liver damage in NAFLD induced by dietary cholesterol. Nutrients 10, (2018).","DOI":"10.3390\/nu10091326"},{"key":"45979_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2119\/molmed.2016.00203","volume":"23","author":"J Henkel","year":"2017","unstructured":"Henkel, J. et al. Induction of steatohepatitis (NASH) with insulin resistance in wild-type B6 mice by a western-type diet containing soybean oil and cholesterol. Mol. Med. 23, 70\u201382 (2017).","journal-title":"Mol. Med."},{"key":"45979_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/hep.25789","volume":"57","author":"C Savard","year":"2013","unstructured":"Savard, C. et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 57, 81\u201392 (2013).","journal-title":"Hepatology"},{"key":"45979_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cmet.2006.07.006","volume":"4","author":"M Mar\u00ed","year":"2006","unstructured":"Mar\u00ed, M. et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell. Metab. 4, 185\u2013198 (2006).","journal-title":"Cell. Metab."},{"key":"45979_CR25","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/hep4.1348","volume":"3","author":"GN Ioannou","year":"2019","unstructured":"Ioannou, G. N. et al. Cholesterol crystals in hepatocyte lipid droplets are strongly associated with human nonalcoholic steatohepatitis. Hepatol. Commun. 3, 776\u2013791 (2019).","journal-title":"Hepatol. Commun."},{"key":"45979_CR26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1194\/jlr.M072454","volume":"58","author":"GN Ioannou","year":"2017","unstructured":"Ioannou, G. N. et al. Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH. J. Lipid Res. 58, 1067\u20131079 (2017).","journal-title":"J. Lipid Res."},{"key":"45979_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jacl.2020.07.003","volume":"14","author":"SM Nidorf","year":"2020","unstructured":"Nidorf, S. M., Fiolet, A. & Abela, G. S. Viewing atherosclerosis through a crystal lens: How the evolving structure of cholesterol crystals in atherosclerotic plaque alters its stability. J. Clin. Lipidol. 14, 619\u2013630 (2020).","journal-title":"J. Clin. Lipidol."},{"key":"45979_CR28","doi-asserted-by":"publisher","first-page":"e11765","DOI":"10.1371\/journal.pone.0011765","volume":"5","author":"K Rajam\u0308aki","year":"2010","unstructured":"Rajam\u0308aki, K. et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: A novel link between cholesterol metabolism and inflammation. PLoS One. 5, e11765 (2010).","journal-title":"PLoS One"},{"key":"45979_CR29","doi-asserted-by":"publisher","first-page":"968366","DOI":"10.3389\/fimmu.2022.968366","volume":"8","author":"AC Maretti-Mira","year":"2022","unstructured":"Maretti-Mira, A. C., Salomon, M. P., Hsu, A. M., Kanel, G. C. & Golden-Mason, L. Hepatic damage caused by long-term high cholesterol intake induces a dysfunctional restorative macrophage population in experimental NASH. Front. Immunol. 8, 968366 (2022).","journal-title":"Front. Immunol."},{"key":"45979_CR30","doi-asserted-by":"crossref","unstructured":"Zisser, A., Ipsen, D. H. & Tveden-Nyborg, P. Hepatic stellate cell activation and inactivation in nash-fibrosis\u2014roles as putative treatment targets? Biomedicines 9, 365 (2021).","DOI":"10.3390\/biomedicines9040365"},{"key":"45979_CR31","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/hep.21625","volume":"45","author":"AM El-Badry","year":"2007","unstructured":"El-Badry, A. M. et al. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. Hepatology 45, 855\u2013863 (2007).","journal-title":"Hepatology"},{"key":"45979_CR32","doi-asserted-by":"publisher","unstructured":"Torres, D. M., Williams, C. D., Harrison, S. A. & Features diagnosis, and treatment of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 10, 837\u2013858 https:\/\/doi.org\/10.1016\/j.cgh.2012.03.011 (2012).","DOI":"10.1016\/j.cgh.2012.03.011"},{"key":"45979_CR33","doi-asserted-by":"publisher","first-page":"e82163","DOI":"10.1371\/journal.pone.0082163","volume":"8","author":"M Itoh","year":"2013","unstructured":"Itoh, M. et al. Hepatic crown-like structure: A unique histological feature in non-alcoholic steatohepatitis in mice and humans. PLoS One. 8, e82163 (2013).","journal-title":"PLoS One"},{"key":"45979_CR34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12876-020-01356-2","volume":"20","author":"HH Hansen","year":"2020","unstructured":"Hansen, H. H. et al. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol. 20, 210 (2020).","journal-title":"BMC Gastroenterol."},{"key":"45979_CR35","doi-asserted-by":"publisher","first-page":"10111","DOI":"10.1016\/j.molmet.2020.101111","volume":"50","author":"W Jonas","year":"2021","unstructured":"Jonas, W. & Sch\u00fcrmann, A. Genetic and epigenetic factors determining NAFLD risk. Mol. Metab. 50, 10111 (2021).","journal-title":"Mol. Metab."},{"key":"45979_CR36","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","volume":"10","author":"N Stefan","year":"2022","unstructured":"Stefan, N. & Cusi, K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 10, 284\u2013296 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"45979_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-2275(20)31506-6","author":"M Schwarz","year":"2001","unstructured":"Schwarz, M., Davis, D. L., Vick, B. R. & Russell, D. W. Genetic analysis of intestinal cholesterol absorption in inbred mice. J. Lipid Res. https:\/\/doi.org\/10.1016\/s0022-2275(20)31506-6 (2001).","journal-title":"J. Lipid Res."},{"key":"45979_CR38","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M306022200","author":"L Vergnes","year":"2003","unstructured":"Vergnes, L., Phan, J., Strauss, M., Tafuri, S. & Reue, K. Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J. Biol. Chem. https:\/\/doi.org\/10.1074\/jbc.M306022200 (2003).","journal-title":"J. Biol. Chem."},{"key":"45979_CR39","doi-asserted-by":"publisher","first-page":"e0161","DOI":"10.1097\/HC9.0000000000000161","volume":"7","author":"Y Hosokawa","year":"2023","unstructured":"Hosokawa, Y. et al. Adipose tissue insulin resistance exacerbates liver inflammation and fibrosis in a diet-induced NASH model. Hepatol. Commun. 7, e0161 (2023).","journal-title":"Hepatol. Commun."},{"key":"45979_CR40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","volume":"27","author":"GN Ioannou","year":"2016","unstructured":"Ioannou, G. N. The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol. Metab. 27, 84\u201395 (2016).","journal-title":"Trends Endocrinol. Metab."},{"key":"45979_CR41","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","volume":"15","author":"HK Min","year":"2012","unstructured":"Min, H. K. et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell. Metab. 15, 665\u2013674 (2012).","journal-title":"Cell. Metab."},{"key":"45979_CR42","doi-asserted-by":"publisher","first-page":"159512","DOI":"10.1016\/j.bbalip.2024.159512","volume":"1869","author":"JA Bairos","year":"2024","unstructured":"Bairos, J. A. et al. Sterol O-acyltransferase (SOAT\/ACAT) activity is required to form cholesterol crystals in hepatocyte lipid droplets. Biochim. Biophys. Acta - Mol. Cell. Biol. Lipids. 1869, 159512 (2024).","journal-title":"Biochim. Biophys. Acta - Mol. Cell. Biol. Lipids"},{"key":"45979_CR43","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha, A. R. et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 66, 1037\u20131046 (2017).","journal-title":"J. Hepatol."},{"key":"45979_CR44","doi-asserted-by":"publisher","first-page":"49982","DOI":"10.1074\/jbc.M209649200","volume":"277","author":"VV Kunjathoor","year":"2002","unstructured":"Kunjathoor, V. V. et al. Scavenger receptors class A-I\/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277, 49982\u201349988 (2002).","journal-title":"J. Biol. Chem."},{"key":"45979_CR45","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/liv.12170","volume":"33","author":"V Bieghs","year":"2013","unstructured":"Bieghs, V. et al. Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation. Liver Int. 33, 1056\u20131061 (2013).","journal-title":"Liver Int."},{"key":"45979_CR46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.23998","volume":"53","author":"WK Syn","year":"2011","unstructured":"Syn, W. K. et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 53, 106\u2013115 (2011).","journal-title":"Hepatology"},{"key":"45979_CR47","first-page":"1","volume":"8","author":"KH Kim","year":"2018","unstructured":"Kim, K. H. et al. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice. Sci. Rep. 8, 1\u201314 (2018).","journal-title":"Sci. Rep."},{"key":"45979_CR48","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/hep4.1237","volume":"2","author":"O Glass","year":"2018","unstructured":"Glass, O. et al. Serum Interleukin-8, osteopontin, and monocyte chemoattractant protein 1 are associated with hepatic fibrosis in patients with nonalcoholic fatty liver disease. Hepatol. Commun. 2, 1344\u20131355 (2018).","journal-title":"Hepatol. Commun."},{"key":"45979_CR49","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1038\/s41598-020-60615-0","volume":"10","author":"C Hoffmann","year":"2020","unstructured":"Hoffmann, C. et al. Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis. Sci. Rep. 10, 3850 (2020).","journal-title":"Sci. Rep."},{"key":"45979_CR50","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1038\/ncomms3823","volume":"4","author":"I Mederacke","year":"2013","unstructured":"Mederacke, I. et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun. 4, 2823 (2013).","journal-title":"Nat. Commun."},{"key":"45979_CR51","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"45979_CR52","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"45979_CR53","doi-asserted-by":"publisher","first-page":"e13984","DOI":"10.1371\/journal.pone.0013984","volume":"5","author":"D Merico","year":"2010","unstructured":"Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map: A network-based method for gene-set enrichment visualization and interpretation. PLoS One. 5, e13984 (2010).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45979-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45979-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45979-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:21:10Z","timestamp":1781644870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45979-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["45979"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-45979-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11231"}}